Advertisement

Supportive Care in Cancer

, Volume 10, Issue 2, pp 85–87 | Cite as

Nausea and emesis: still an unsolved problem in cancer patients?

  • Jørn HerrstedtEmail author
Editorial

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wilcox PM, Fetting JH, Nettesheim KM, Abeloff MD (1982) Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy for breast cancer. Cancer Treat Rep 66:1601–1604PubMedGoogle Scholar
  2. 2.
    Roila F, Donati D, Tamberi S, Margutti G (2002) Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10: (this issue)Google Scholar
  3. 3.
    Aapro MS (2002) How do we manage patients with refractory or breakthrough emesis? Support Care Cancer 10: (this issue)Google Scholar
  4. 4.
    Morrow GR, Roscoe JA, Hickok JT, Andrews PLR, Matteson S (2002) Nausea and emesis: evidence for a biobehavioral perspective. Support Care Cancer 10: (this issue)Google Scholar
  5. 5.
    Molassiotis A, Yam BMC, Yung H, Chan FYS, Mok TSK (2002) Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 10 (this issue)Google Scholar
  6. 6.
    Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy- induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819CrossRefGoogle Scholar
  7. 7.
    Gralla RJ, Osoba D, Kris MG, et al (1999) Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol 17:2971–2994PubMedGoogle Scholar
  8. 8.
    ESMO Guidelines Task Force (2001) ESMO recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 12:1059–1060CrossRefGoogle Scholar
  9. 9.
    Holzer P, Schluet W, Maggi CA (1995) Substance P stimulates and inhibits peristalsis via distinct receptors. J Pharmacol Exp Ther 274:322–328PubMedGoogle Scholar
  10. 10.
    Campos D, Pereira JR, Reinhardt RR, et al (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist MK-0869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759–1767PubMedGoogle Scholar
  11. 11.
    Fredrikson M, Hursti TJ, Steineck G, Fürst CJ, Börjesson S, Peterson C (1994) Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J Cancer 70:642–645PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Tanihata S, Igarashi H, Suzuki M, Uchiyama T (2000) Cisplatin-induced early and delayed emesis in the pigeon. Br J Pharmacol 130:132–138PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Yamakuni H, Sawai H, Maeda Y, et al (2000) Probable involvement of the 5-hydroxytryptamine4 receptor in methotrexate-induced delayed emesis in dogs. J Pharmacol Exp Ther 292:1002–1007PubMedGoogle Scholar
  14. 14.
    Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem. Trends over time in controlling chemotherapy- induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 20:113–121PubMedCrossRefGoogle Scholar
  15. 15.
    Osoba D, Zee B, Pater J, et al (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15:116–123PubMedGoogle Scholar
  16. 16.
    De Wit R, Van den Berg H, Burghouts J, et al (1998) Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 77:1487–1491PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Sigsgaard T, Herrstedt J, Handberg J, Kjær M, Dombernowsky P (2001) Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 19:2091–2097PubMedGoogle Scholar
  18. 18.
    Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1–5CrossRefGoogle Scholar
  19. 19.
    Tsukuda M, Furukawa S, Kokatsu T, Enomoto H, Kubota A, Furukawa M (1995) Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy. Eur J Cancer [A] 31:1647–1649CrossRefGoogle Scholar
  20. 20.
    Lee C-W, Suh C-W, Lee J-S, et al (1994) Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. J Korean Med Sci 9:369–375PubMedCentralPubMedGoogle Scholar
  21. 21.
    Lebeau B, Depierre A, Giovannini M, et al (1997) The efficacy of combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with dual antiemetic treatment in cisplatin-based chemotherapy. Ann Oncol 8:887–892PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  1. 1.Department of Oncology 54 B1, Copenhagen University Hospital Herlev, DK-2730 HerlevDenmark

Personalised recommendations